BioShares Biotechnology Technical Analysis

BioShares Biotechnology Clinical Trials -- USA Etf  

USD 29.97  0.98  3.16%

BioShares Biotechnology Clinical Trials shows Downside Deviation of 1.39, Risk Adjusted Performance of 0.1634 and Mean Deviation of 1.17. BioShares Biotechnology technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the entity future prices. In plain English you can use this information to find out if the entity will indeed mirror its model of historical prices and volume momentum or the prices will eventually revert. We found nineteen technical drivers for BioShares Biotechnology Clinical Trials which can be compared to its rivals. Please confirm BioShares Biotechnology Maximum Drawdown, Semi Variance and the relationship between Jensen Alpha and Potential Upside to decide if BioShares Biotechnology is priced correctly providing market reflects its regular price of 29.97 per share.
 Time Horizon     30 Days    Login   to change

BioShares Biotechnology Technical Analysis

Indicator
Time Period
  Portfolio Optimization    
  
Execute Indicator
 
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of BioShares Biotechnology volatility. High ATR values indicate high volatility, and low values indicate low volatility. View also all equity analysis or get more info about average true range volatility indicators indicator.

BioShares Biotechnology Trend Analysis

Use this graph to draw trend lines for BioShares Biotechnology Clinical Trials. You can use it to identify possible trend reversals for BioShares Biotechnology as well as other signals and approximate when it will take place. Remember, you need at least two touches of the trend line with actual BioShares Biotechnology price movement. To start drawing, click on the pencil icon on top-right. To remove the trend, use eraser icon.

BioShares Biotechnology Best Fit Change Line

The following chart estimates an ordinary least squares regression model for BioShares Biotechnology Clinical Trials applied against its price change over selected period. The best fit line has a slop of 0.17 % which may imply that BioShares Biotechnology Clinical Trials will maintain its good market sentiment and make money for investors. It has 34 observation points and a regression sum of squares at 24.16, which is the sum of squared deviations for the predicted BioShares Biotechnology price change compared to its average price change.

Did you try this?

Run Watchlist Optimization Now
   

Watchlist Optimization

Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Hide  View All  NextLaunch Watchlist Optimization
BioShares Biotechnology Clinical Trials is the top ETF in mean deviation as compared to similar ETFs. It is currently under evaluation in standard deviation as compared to similar ETFs creating about  1.26  of Standard Deviation per Mean Deviation. The ratio of Standard Deviation to Mean Deviation for BioShares Biotechnology Clinical Trials is roughly  1.26 

One Year Return

BioShares Biotechnology One Year Return
Based on recorded statements BioShares Biotechnology Clinical Trials has One Year Return of 56%. This is 352.42% higher than that of the Bio Shares family, and 352.6% higher than that of Health category, The One Year Return for all etfs is 4588.0% lower than the firm.
  Year Return 
      BioShares Biotechnology Comparables 
Although One Year Fund Return indicator can give a sense of overall fund short-term potential, it is recommended to look at mid and long term return measure before selecting a particular fund or ETF. The great way to validate fund short-term performance is to compare it with other similar funds or ETFs for the same 12 months interval.